X
GSK enters PARP space with TESARO acquisition
https://pharmaphorum.com/news/gsk-enters-parp-space-with-tesaro-acquisition/
Tesaro
Clovis’ PARP drug gets new US ovarian cancer use
Rucaparib gets FDA OK in maintenance use
Clovis’ Rubraca close to EU approval in ovarian cancer
CHMP backs conditional approval for PARP drug
Tesaro and Roche to combine drugs in bladder cancer trials
Tesaro is to combine its PARP-inhibitor drug Zejula with Roche’s PD-L1 immunotherapy Tecentriq in clinical trials for metastatic bladder cancer.
AZ’s Lynparza becomes first PARP drug approved in breast cancer
Lynparza first in class approved in breast cancer
Clovis PARP drug gets fast US review in new ovarian cancer use
Impressed by survival data, FDA hastens review in expanded patient group
Tesaro gets European approval on Zejula, set to challenge AZ
Tesaro’s PARP drug approved in wider ovarian cancer population
1 2
